Please login to the form below

Not currently logged in
Email:
Password:

SGLT-2

This page shows the latest SGLT-2 news and features for those working in and with pharma, biotech and healthcare.

FDA panel backs CV claims for Novo Nordisk's Victoza

FDA panel backs CV claims for Novo Nordisk's Victoza

The positive vote from EMDAC puts us one step closer to expanding our offering to reduce the risk of cardiovascular events in people with type 2 diabetes.". ... Victoza is the second drug to get a recommendation for improving cardiovascular outcomes in

Latest news

  • AZ gets US approval for diabetes combo Qtern AZ gets US approval for diabetes combo Qtern

    The US FDA has approved AstraZeneca's Qtern, a two-drug therapy for type 2 diabetes, after rejecting the drug in 2015. ... The approval of Qtern is good news for patients who may benefit from improved glycaemic control by adding a DPP-4 inhibitor to a

  • New Jardiance label could boost sales by $1.7bn, says analyst New Jardiance label could boost sales by $1.7bn, says analyst

    New Jardiance label could boost sales by $1.7bn, says analyst. Diabetes treatment can reduce the risk of cardiovascular death in type 2 patients. ... It is the first time that any diabetes treatment has been approved with a cardiovascular claim and -

  • AZ looks beyond diabetes with Forxiga trials AZ looks beyond diabetes with Forxiga trials

    The company is also starting new mechanistic trials designed to understand "the underlying science behind the potential cardiovascular and renal protective signals seen with the SGLT-2 inhibitor class". ... Boehringer and Lilly have already reported a

  • NICE backs freer use of SGLT2 inhibitors for diabetes NICE backs freer use of SGLT2 inhibitors for diabetes

    to prescribe SGLT 2 inhibitors when they feel it is appropriate". ... The committee agreed that people with diabetes and their clinicians would value having an additional treatment option to help manage their type 2 diabetes - which this positive

  • Novo Nordisk says Victoza outperforms SGLT2 inhibitors Novo Nordisk says Victoza outperforms SGLT2 inhibitors

    targets. The analysis included 17 randomised controlled trials that included people with type 2 diabetes who were inadequately controlled with metformin alone or in combination with sulfonylurea, DPP4 inhibitors or glitazone ... versus SGLT-2 inhibitors

More from news
Approximately 7 fully matching, plus 25 partially matching documents found.

Latest Intelligence

  • Deal Watch November 2015 Deal Watch November 2015

    2, 700. Cardioxyl Pharmaceuticals. Bristol-Myers Squibb. Acquisition - company. Lead asset: p2 CXL-1427, nitroxyl (HNO) donor (prodrug) - iv treatment for acute decompensated heart failure (ADHF). ... 2, 075. Lexicon Pharmaceuticals. Sanofi. Collaboration

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

Lars Bruening
Shaping healthcare
Bayer’s Lars Bruening talks about moving to the UK as the market works its way through a series of seismic changes...
No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...

Infographics